Acalabrutinib and breast feeding

From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

No information is available on the clinical use of acalabrutinib during breastfeeding. Because acalabrutinib is over 97% bound to plasma proteins, and the half-life of the drug and metabolite are less than 7 hours, the amount in milk is likely to be low. However, the protein binding of the active metabolite is not known and the manufacturer recommends that breastfeeding be discontinued during acalabrutinib therapy and for at least 2 weeks after the final dose.

Latest research

PubMed

Up to date info

UpToDate

Alternative drugs - Acalabrutinib and breast feeding

Suggested alternatives on Acalabrutinib and breast feeding, when available and appropriate.

Breast feeding and drugs

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

External links

Wikipedia
Medicine icon
Medicine icon

This WikiMD article Acalabrutinib and breast feeding is a stub. If you are familiar with the topic Acalabrutinib and breast feeding, you can help us. Paid editors welcome!


 

Acalabrutinib and breast feeding is part of WikiMD's free ^articles!

^Acalabrutinib and breast feeding (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available